Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Instagram Outage Disrupts Thousands of U.S. Users 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
MORGANTOWN, W.Va., Nov. 10, 2016 -- Protea Biosciences Group, Inc., (OTCQB:PRGB) announced today that the Company has appointed David Halverson as its President.
“We are pleased to announce the selection of David Halverson as President of Protea Biosciences,” stated Steve Turner, Protea’s Chairman & CEO. He added, “David has led the successful development of our proprietary molecular information services business. He is building a strong and growing customer base, which now includes major pharmaceutical and biotechnology companies; he is ideally suited to manage our business operations, as we position Protea to meet and lead the global demand for better molecular information, for improved pharmaceutical development.”
David Halverson commented, “I am honored to be appointed to the position of President, as we continue to grow the company and add amazing new capabilities to our expanding portfolio of proprietary Metabolic, Proteomic, Biopharmaceutical, and Mass Spec Imaging workflows. I have the highest confidence in our Company achieving the leadership position in the new molecular information services industry.”
Prior to his appointment as President, Halverson served as Protea’s Vice President and Chief Business Officer. Before joining Protea, Halverson was employed by Huntingdon Life Sciences in various capacities, including Head of European and US Sales. He has over 20 years of management experience in the pharmaceutical services industry, including serving as a Director of Sales for PPD Discovery and the Quintiles Preclinical Groups.
About Protea Biosciences
Protea Biosciences Group, Inc. (OTCQB:PRGB) is a leading molecular information company providing proprietary bio-analytical technology to the pharmaceutical and life science industries. "Molecular information" refers to the generation and bioinformatic processing of very large data sets, obtained by applying the Company's proprietary technology to identify and characterize the proteins, metabolites, lipids and other biomolecules which are the byproducts of all living cells and life forms.
Protea is a registered trademark of Protea Biosciences Group, Inc.
For more Information: Protea Biosciences Group, Inc., 1311 Pineview Dr., Morgantown, WV 26505 USA Phone: 304.292.2226 Fax: 304.606.3049 https://proteabio.com/investors [email protected]
